Volume 1.38 | Dec 11

Intestinal Cell News 1.38 December 11, 2015
Intestinal Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ICN on Twitter
Interleukin-22 Promotes Intestinal-Stem-Cell-Mediated Epithelial Regeneration
Using ex vivo organoid cultures, scientists showed that innate lymphoid cells, potent producers of interleukin-22 (IL-22) after intestinal injury, increase the growth of mouse small intestine organoids in an IL-22-dependent fashion. Recombinant IL-22 directly targeted intestinal stem cells (ISCs), augmenting the growth of both mouse and human intestinal organoids, increasing proliferation and promoting ISC expansion. [Nature] Abstract
Free Sample: TeSR™2 Defined, Feeder-Free and Xeno-Free Human ES and iPS Cell Medium
PUBLICATIONS (Ranked by impact factor of the journal)

The Msi Family of RNA-Binding Proteins Function Redundantly as Intestinal Oncoproteins
Scientists demonstrated that MSI1 and MSI2 act as functionally redundant oncoproteins required for the ontogeny of intestinal cancers. [Cell Rep] Full Article | Graphical Abstract

Up-Regulation of REG3A in Colorectal Cancer Cells Confers Proliferation and Correlates with Colorectal Cancer Risk
Scientists explored the biological function and the underlying molecular mechanism of regenerating islet-derived 3 alpha (REG3A) in colorectal cancer (CRC). REG3A was found elevated in CRC compared with normal tissues. [Oncotarget] Full Article

Profiles of microRNA Networks in Intestinal Epithelial Cells in a Mouse Model of Colitis
The authors aimed to uncover the regulatory microRNA-target gene relationships that arise differentially in inflamed small- compared with large-intestinal epithelial cells. [Sci Rep] Full Article

FAT4 Functions as a Tumor Suppressor in Gastric Cancer by Modulating Wnt/β-Catenin Signaling
The authors investigated the role of FAT4 in gastric cancer and examined the underlying molecular mechanisms. FAT4 had a tumor suppressor role mediated by the modulation of Wnt/β-catenin signaling, providing potential novel targets for the treatment of gastric cancer. [Br J Cancer] Abstract

Epithelial Sel1L Is Required for the Maintenance of Intestinal Homeostasis
The authors showed that the expression of SEL1L and HRD1, the most conserved branch of mammalian ERAD, is significantly reduced in ileal Crohn’s disease. [Mol Biol Cell] Abstract

Hes1 Increases the Invasion Ability of Colorectal Cancer Cells via the STAT3-MMP14 Pathway
Investigators explored the role of hairy/enhancer of split (HES) in the tumorigenesis of colorectal cancer. Knocking down Hes1 induced colorectal cancer cell senescence and decreased the invasion ability, whereas over-expression of Hes1 increased STAT3 phosphorylation activity and up-regulated MMP14 protein level. [PLoS One] Full Article

RhoA Is Associated with Invasion and Poor Prognosis in Colorectal Cancer
The authors investigated the functional importance of RhoA using human cell lines as well as 150 colorectal cancer patient-derived samples as it remains unclear whether RhoA functions as either an oncogene or a tumor suppressor in colon cancer. [Int J Oncol] Abstract

Permeability of Plumbagin across Human Intestinal Cell In Vitro
Researchers investigated the permeability of plumbagin across Caco-2 cell monolayer and its effects on the expression and function of P-glycoprotein. [Arch Pharm Res] Abstract


Fasting Protects Mice from Lethal DNA Damage by Promoting Small Intestinal Epithelial Stem Cell Survival
Scientists demonstrated that fasting preserves small intestinal (SI) architecture by maintaining SI stem cell viability and SI barrier function following exposure to high-dose etoposide. [Proc Natl Acad Sci USA] Abstract

Free wallchart: The Intestinal Crypt
Constructing Personalized Longitudinal Holo’omes of Colon Cancer-Prone Humans and Their Modeling in Flies and Mice
The intestinal holo’ome–defined as the combination of host and microbiota genomes, transcriptomes, proteomes, and metabolomes–may be imbalanced and shift to disease when the wrong host gene expression profile meets the wrong microbiota composition. [Oncotarget] Full Article

Visit our reviews page to see a complete list of reviews in the intestinal cell research field.
First Experimental Results for the Treatment of Colitis with Viaskin® will be presented at the Crohn’s & Colitis Foundation of America’s 2015 Advances in IBD Conference (AIBD)
DBV Technologies announced that a communication on experimental results on the use of epicutaneous immunotherapy in a model of Crohn’s disease will be presented. [Press release from DBV Technologies discussing research to be presented at the Crohn’s & Colitis Foundation of America Advances in Inflammatory Bowel Diseases (AIBD), Orlando] Press Release

From our sponsor: Learn about detecting cancer stem cells with ALDEFLUOR™. Watch the webinar.
Janssen Submits Applications Seeking Approval of STELARA® in United States and European Union for Crohn’s Disease
Janssen Biotech, Inc. and Janssen-Cilag International NV announced the submission of a Biologics License Application to the United States Food and Drug Administration and a Grouped Type II Variation/Extension Application to the European Medicines Agency seeking approval of STELARA® for the treatment of adult patients with moderately to severely active Crohn’s disease. [Janssen Biotech, Inc. (PR Newswire Association LLC.)] Press Release

Synthetic Biologics’ SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase II Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
Synthetic Biologics, Inc. announced positive topline results from the four week Phase II clinical trial of SYN-010 for the treatment of irritable bowel syndrome with IBS-C. [Synthetic Biologics, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cancer as an Evolving and Systemic Disease
March 12-15, 2016
New York City, United States

Visit our events page to see a complete list of events in the intestinal cell research community.
NEW PhD Student – Colorectal/Pancreatic Cancer (German Cancer Research Center)

NEW Postdoctoral Fellow – Cancer Immunotherapy (Inserm)

Postdoctoral Scientist – Gastroenterology and Immunology (University of Oxford)

Research Associate – Immunology and Inflammation (Imperial College London)

Research Technician – Preclinical and Translational Research (Qu Biologics Inc.)

Faculty Position – Autoimmune Disease and Rheumatologic Inflammation (Cleveland Clinic)

Computational Postdoctoral Associate – Inflammatory Bowel Disease (Icahn School of Medicine at Mount Sinai)

Postdoctoral Associate – Epigenetics of Inflammatory Bowel Disease (Icahn School of Medicine at Mount Sinai)

Open Group Leader Position – Cancer Research (Oslo University Hospital)

Postdoctoral Research Fellow – Ex Vivo Tumor Organoid Models (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Intestinal Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Intestinal Cell News: Archives | Events | Contact Us